Orthofix Medical Inc. (OFIX) stock intrinsic value fair value estimate & owner earnings analysis

Orthofix makes spinal implants, biologics and the 7D FLASH surgical navigation system, bone growth stimulators, and external fixation devices for limb reconstruction. In 2025 it had $822 million of sales: $247 million from Bone Growth Therapies (up 5.9%), $135 million from Global Limb Reconstruction (up 8.4%), and the rest from spinal implants and biologics, most of it added through the January 2023 all-stock merger with SeaSpine. About 83% of sales are in the United States. What the business earns for its owners. We measure the cash left after the business keeps itself running: operating cash flow with short-term working-capital swings taken out, less the cost of paying staff in stock, less the capital spending needed to keep the existing business going, mostly the loaner sets of surgical instruments that spine companies place with hospitals. We also count inventory written off as a cost, because the company spends real cash building implant sets that later become obsolete, and that charge has risen from $11 million in 2021 to $31 million in 2025. On that basis Orthofix produced about $19 million to $42 million a year from 2016 to 2020 ($0.97 to $2.28 a share), but has produced negative cash for owners every year since the SeaSpine merger: -$117 million in 2023, -$46 million in 2024 and -$40 million in 2025 (-$1.00 a share). Before interest, the business itself lost about $22 million of cash in 2025, after losing $29 million in 2024. The first half of 2026 was weaker again: operating cash flow was -$24 million against -$7 million a year earlier, and in January the company drew the remaining $65 million of its term loan for working capital. Which years we use. The earlier, profitable years describe a smaller, different company before the merger nearly doubled the share count, so we measure the business from 2023 on. Those three years have all been negative, so there is no positive normal level to anchor on. Each case therefore starts from today's cash loss and only credits improvement we can point to: merger integration costs ($6 million in 2025 versus $14 million in 2024), the end of the M6 artificial disc lines discontinued in 2025 ($17 million of charges), and lower litigation and executive succession costs. Bone Growth Therapies is the one part with a steady, demonstrated growth record (from $171 million in 2020 to $247 million in 2025), and we credit its continued mid-single-digit growth only in the base and bull cases. The debt. Orthofix owes about $225 million on term loans from Oxford Finance plus about $18 million of finance leases. The loans cost at least 8.75%, interest-only until December 2028, then amortize and mature in November 2029. Covenants require minimum liquidity and a maximum debt-to-EBITDA ratio, and the lender has discretion over a further $50 million. We count cash beyond what the covenants and operations need, and add about $18 million for the extra cost of borrowing at 8.75% for three more years. Net debt is about $185 million, or roughly $4.50 a share. Bear case: cash losses continue at about $30 million a year for two years as the spinal implant business keeps losing ground and inventory write-offs stay near $30 million, and the industry's own record supplies a downturn: elective spine procedures fell sharply in the 2020 shutdown, when Orthofix's sales dropped 12%. The business never gets back above break-even before the 2029 maturity, and refinancing $225 million against negative cash flow would mean expensive new money or heavy dilution. The business is worth roughly -$90 million on these flows against $185 million of net debt, leaving about -$6.65 a share: the company would owe far more than it is worth, by around $270 million. Base case: losses narrow from about $20 million next year to break-even in year three as merger, M6 and legal costs fall away, and business cash flow reaches about $20 million a year by year six, carried by Bone Growth Therapies and limb reconstruction, then held flat. The business is worth about $243 million against $185 million of net debt, leaving about $58 million or $1.41 a share. In this case the business barely covers its roughly $20 million interest bill by the late 2020s, so the 2029 refinancing is tight even here. Bull case: the company's identified levers work - integration savings land, inventory write-offs fall back toward pre-merger levels, Bone Growth Therapies keeps compounding and U.S. limb reconstruction keeps growing double digits - and business cash flow climbs to about $40 million a year, close to what the smaller pre-merger company earned. The business is worth about $556 million against $185 million of net debt, or about $9.07 a share. We did not credit new product launches, share gains in spine, or the 7D navigation installed base as drivers, because none has yet produced positive cash for the combined company. What could go wrong beyond the cases. An FDA panel recommended in 2020 that bone growth stimulators be moved from Class III to Class II, which would lower the barrier for competitors in the one segment that reliably earns money. Bone growth revenue is billed largely to insurers and is subject to payor review and adjustment. Margin of safety price. We are not sure of the earnings level at all: there is no year since the merger in which the combined company produced cash for its owners, and the most recent half-year was worse, not better. The worst plausible outcome - continued losses into the 2029 maturity with lenders in control - leaves common shareholders with nothing, and the structure (secured lender with covenants, concentration of profit in one regulated product line) would not protect them. If we are wrong about how fast merger costs fall away, or about inventory write-offs, the base case value disappears. The business pays no dividend. The margin-of-safety price does not rest on price alone. Once the company demonstrates four straight quarters in which operating cash covers capital spending and stock compensation, the base case becomes credible and the margin-of-safety price is $1.00 a share, a price at which even a modest, sustained level of business cash flow after the debt is paid implies returns well above the target. Changes since our previous analysis. The earlier estimate measured cash before stripping out working-capital swings and before treating inventory write-offs as a cost, so its figures are not comparable. What has changed in the business is that the first half of 2026 burned more cash than a year earlier and the company drew its remaining $65 million of term loan.